Primer: Iambic Therapeutics (IAM US) - Oct 2026
Iambic Therapeutics is a clinical-stage biotechnology company deploying a differentiated 'Molecular Superintelligence' platform that integrates...
95 Views
Iambic Therapeutics (IAM US): Synthetic Expert Call Transcript (01 Oct 2026)
The Platform-Collaboration Pivot Point: Big Pharma’s transition from skeptical "pilot" programs to high-value platform-licensing deals is driven...
94 Views
Iambic Tx IPO First-Read: AI Models Enchant/NeuralPLexer, IAM1363 (Type II HER2i), Partnerships
NVIDIA-backed AI drug discovery Iambic Tx filed S1 last week. Our first-take: 1) its flagship AI models Enchant/NeuralPLexer, 2) clinical-stage...
97 Views